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The Ethics of Global Psychiatric Genomics: Multilayered Challenges to Integrating 
Genomics in Global Mental Health and Disability 
A Position Paper of Oxford Global Initiative in Neuropsychiatric GenEthics (NeuroGenE) 
 
Summary 
Psychiatric genomics has the potential to radically improve prevention and early intervention of 
serious mental and neurodevelopmental disorders worldwide. However, little work has been done on 
the ethics of psychiatric genomics – an oversight that could result in poor local uptake, reduced 
practical / clinical application, and ethical violations in this rapidly developing area of scientific 
research. As part of the Global Project of the Stanley Center for Psychiatric Research, the Global 
Initiative in Neuropsychiatric GenEthics (NeuroGenE) based at the University of Oxford aims to 
embed ethical inquiry within scientific investigation and engage with fundamental ethical questions 
around a psychiatric genomic approach to mental and neurodevelopmental disorder. This position 
paper sets out the core aims of the NeuroGenE research programme and explores the importance of a 
cross-cutting research orientation using multidisciplinary methodologies to ensure efforts to translate 
and apply global psychiatric genomics in public policy and clinical practice are ethically grounded. 
 
Introduction / Rationale 
Psychiatric genomics research has accelerated rapidly in recent years and now forms a core pillar of 
major scientific and mental health research programs. Through population wide association studies, 
psychiatric genomics examines the biogenetic causes for neurological traits underlying major 
psychiatric disorders, with the goal of generating a more nuanced psychiatric nosology and improve 
preventative and targeted treatments within a precision-medicine framework.
1,2
 Thus far, genome-
wide association studies have mainly targeted samples from European populations. Recognising the 
need to diversify representative populations, the Global Project of the Stanley Center for Psychiatric 
Research at the Broad Institute has embarked on an ambitious initiative to broaden sample collections 
of populations within sub-Saharan Africa, (Kenya, Ethiopia, Uganda, South Africa), Asia (China and 
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Japan), and eventually South America, in order to probe the underlying biological mechanisms for 
mental and neurodevelopmental disorders (such as ADHD and autism).  
 
In theory, psychiatric genomics presents a potentially transformative approach that could rapidly 
advance precision medicine in the field of psychiatry in the global context. As laudable as this aim is, 
there are significant concerns in terms of how its goals and aspirations are to succeed in the global 
context: first, psychiatric genomics will not be practically applicable if there is little engagement with 
a range of ethical issues that are raised in this approach; second, there is a risk that ethical violations 
could occur in research and application if these issues are not examined carefully. The ethics of 
psychiatric genomics from local and global perspectives has garnered little attention thus far but the 
very limited literature which exists has focused on potential implications of this approach to mental 
health in deepening or alleviating genetic essentialism and stigma, as well as individualising patients 
to the detriment of social and relational contexts.
3,4,5
 Yet such a research agenda is urgently needed to 
ensure that pressing ethical considerations remain foremost in practical and clinical applications, 
utilising interdisciplinary bioethical research strategies to explore the mechanisms which lead to 
genetic essentialist views.
6,7
  
 
This position paper sets out the core aims of the NeuroGenE research programme through a review of 
key debates within global mental health, genomics, and disability studies. We also explain the 
project’s methodological approach, guiding principles, and expected outputs.  
 
Aims of NeuroGenE 
NeuroGenE is a multilayered research and training programme focused on the ethics of psychiatric 
genomics within the global context. The ultimate goal of the programme is to ensure the responsible 
conduct and uses of scientific research, such that the research contributes to improvements in the 
treatment of and respect for persons facing mental health challenges, their families and their carers. 
An equally important, parallel goal is to identify how scientific research on psychiatric genomics can 
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best respect and benefit local communities including local stakeholders, practitioners, and scientific 
infrastructures.  
 
The NeuroGenE project is structured along three related levels of research: (i) pragmatic inquiry; (ii) 
substantive inquiry; and (iii) policy / practice application. Pragmatic inquiry examines the ethical 
questions embedded within scientific investigation of psychiatric genomic data, including issues 
related to data collection and ownership, biobanking, and research procedure. Substantive inquiry 
critically examines deeper questions around the conceptual grounding, cultural translation, and 
normative implications of a psychiatric genomics lens to mental health within the global setting. 
These two levels of inquiry will feed into investigations on policy / practice application, exploring 
how an ethically grounded approach to psychiatric genomics should inform national and international 
policies in public health, as well as local practices of community mental health treatment. 
  
Current Status of Research 
The ethics of psychiatric genomics intersects with the existing fields of research within genomics, 
global mental health, and disability studies, each of which are motivated and informed by specific 
practical concerns and normative orientation. Alongside scientific research into the genomics of 
physical conditions, ethical discussions have explored core procedural issues around the protection of 
research participants (e.g. community consent and consultation) and scientists in low-income 
countries (e.g. data-sharing and capacity-building), as well as the regulatory mechanisms of 
international collaborations (e.g. sample storage and ownership).
8,9,10
 Questions of genetic identity, 
responsibility, and the ethics of return of results have also been part of substantive bioethical 
discussions within the clinical context.
11,12,13
 
 
Meanwhile, global mental health discussions readily identify the urgent need for collective action, 
investment, and innovative solutions to address chronic inequality and poor delivery of mental health 
care in the global context.
14,15
 Gaps in treatment and care, both within and across countries – remain 
foremost in these debates. Other strands of global mental health focus on the justification of a global 
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mental health framework to local cultural contexts, beliefs, and social practices around mental 
disorder, sometimes questioning the portability of standard diagnostic tools and treatment 
recommendations.
16,17
  
 
Recent research in disability studies echoes this scepticism towards standard diagnostic tools, both for 
treatment and research, and highlight instead the systemic structures (i.e. public policy, laws, societal 
norms) that discriminate against and inhibit the full respect of persons with disabilities – including 
those with mental and neurodevelopmental disorders. Increasingly important in disability studies is 
the co-production of knowledge by persons with disabilities and survivors of psychiatry in alignment 
with a human rights lens that recognises their right to equal participation and structural 
accommodations.
18,19,20
 
 
On one hand, critical engagement with relevant discussions internal to genomics, global mental 
health, and disability studies is necessary in order to clarify the role of psychiatric genomics in 
improving mental health care and advancing advocacy efforts to promote the rights of individuals 
with mental and neurodevelopmental disorders. On the other hand, each field of inquiry in isolation 
captures only a partial picture of the complex ethical challenges facing the research and practical 
application of psychiatric genomics. Overcoming these challenges will ultimately depend on detecting 
where the ethical faultlines lie in the first instance. This demands an original cross-cutting approach 
that generates dialogue between these debates rather than a singular research orientation (Fig.1).  
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Figure 1: NeuroGenE Programme of Research 
 
Importantly, these different areas of research have yet to be bridged in a single programme of inquiry. 
As it stands, the existing literature in each respective field of study has failed to detect the need for 
such a cross-cutting approach in order to address the fundamental ethical issues at stake as global 
psychiatric genomics rapidly advances. A broadened intellectual orientation is necessary if innovative 
ethical inquiry and solutions are to be developed and as we discuss below, three major ethical 
faultlines are brought into sharp relief once a cross-cutting approach is adopted. 
 
Dimensional Approaches of Mental Disorder and Disability 
One major faultline in psychiatric genomics revolves around the concept of mental health and 
possible tensions with a disability rights ethos. Psychiatric genomics tracks important conceptual 
changes in mental health, moving away from dichotomous classifications of ‘health’ and 
‘disease/illness’ and towards a more dimensional understanding which accommodates a spectrum of 
experiences between mental health to disorder and disability.
21
 Psychiatric genomics reveals a 
symptom spectra: risk alleles for mental disorders can be present in both affected and unaffected 
people, whilst multiple disorders have common genetic aetiology and environmental risk factors.
22,23,24
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Not only do these findings invite greater nuance to diagnostic classifications of mental disorder, but 
the range of interventions is also broadened to encompass prevention and early intervention strategies 
in addition to treatment and rehabilitation.
25,26,27
 
 
At first glance, this dimensional approach appears consistent with recent changes to classifications of 
disability. The World Health Organization’s International Classification of Functioning, Disability 
and Health (ICF) similarly charts health and disability along a multidimensional continuum based on 
a taxonomy of body functions, corresponding body structures, and contextual, environmental, and 
personal factors that impact on components of body functioning.
28,29
 Functioning and disability are 
conceived as universal phenomena that all people experience over the life-span. Echoing this 
spectrum view is the UN Convention of the Rights of Persons with Disabilities (CRPD), a potentially 
transformative human rights framework that articulates the rights and obligations owed to individuals 
with disabilities, to accommodate a diverse range of bodily and intellectual functionings. Recent 
disability studies and advocacy work have therefore focused on securing crucial protections for 
persons with disabilities based around an ethos of respect for bodily difference, protection of 
autonomy, participation in all areas of life, and non-paternalism.
30–33
 
 
Fundamental tensions between the dimensional approaches to mental health and disability are 
nonetheless revealed once a cross-cutting perspective is adopted. First, within a dimensional approach 
to mental health, the criterion of functional impairment continues to be used as a threshold measure by 
which a person can be diagnosed with a disorder that prima facie warrants clinical treatment and 
rehabilitation. From the perspective of disability studies, however, this threshold concept of functional 
impairment might be viewed as discriminatory and prejudicial, where it is used to presume the loss of 
decision-making competence, question the authenticity of a person’s deliberation and choices, or 
justify (coercive or non-coercive) interventions. Indeed the ICF’s concept of functionality has little to 
do with setting a threshold to separate ‘prevention’ from ‘treatment’, but instead provides the 
foundation for a tool to collect more accurate population-based disability statistics (via census and 
national survey) as a means of monitoring the international implementation of the CRPD.
34
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The second tension touches on even more profound ethical issues around the putative justifiability of 
prevention / early intervention in mental health care and the role of psychiatric genomics. Improved 
scientific understanding of underlying genetic mechanisms could help develop early biomarkers and 
precision medicine in psychiatry, focused mainly on the early detection (and prevention) of mental 
disorder and disability. But this aspiration of psychiatric genomics may be ethically problematic 
through the lens of disability activism and research, where neurological difference is increasingly 
recognised as identity difference, and efforts to ‘fix’ the individual’s traits that are typically associated 
with the disability can be viewed as discriminatory.
35
 This view welcomes support and may even 
advocate for appropriate treatment, yet also critically challenges the concept of the individual being 
considered ‘abnormal’ with the expectation that they should immediately adjust to societal norms, 
either voluntarily or through coercive means.
36,37,38
 
 
The dimension of cultural context adds further complexity to these tensions. For example, though 
various African countries are signatories of human rights conventions which expressly support a 
disability rights paradigm, such as the CRPD,
39
 cultural perspectives on disability vary, often resting 
on the extent to which traditional or religious conceptual frameworks and healing practices can 
support and accept individuals with mental and neurodevelopmental disorders.
40,41
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In sum, the aspiration to facilitate prevention and early intervention strategies means psychiatric 
genomics raises core questions around the societal and clinical acceptance of neurological disorders in 
different cultural contexts, see Box 1. 
 
 
The Dilemma of the Global and the Local 
Another major ethical faultline clusters around the dilemmas of navigating the global and the local at 
multiple levels of psychiatric genomics. These range from culturally specific issues around informed 
consent procedures, to questions of translation and cultural understanding of genomics and mental 
disorder, to fundamental issues around global equity and distributive justice. Here we focus on the 
latter two issues to highlight the importance of our cross-cutting approach. 
 
The Stanley Initiative seeks to expand genetic samples to accurately represent a global population, 
with the recognition that genomics research requires contextualised data and the involvement of non-
Box 1: Core Ethical Questions on the Impact of Psychiatric Genomics on the Approaches of 
Mental Disorder and Disability 
 Does the early intervention prism of psychiatric genomics imply (i) the 
pathologisation of certain behavioural conditions and (ii) the aspiration to cure the 
individual or prevent the individual from developing certain disorders? How can the 
prevention and early intervention lenses of psychiatric genomics balance the 
imperative towards better life outcomes for people with mental and 
neurodevelopmental disorders on one hand, with respect for and acceptance of such 
individuals on the other? 
 Would genomic responsibility suggest individuals and their family members are 
obligated to engage in preventative or early intervention strategies?  
 How does psychiatric genomics affect notions of personhood and personal identity 
amongst individuals with mental and neurodevelopmental disorders? 
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Western stakeholders in lower- and middle-income settings. The ‘global’ nature of psychiatric 
genomics discourse itself, however, needs to be questioned more carefully. The wide variation 
between local belief systems around mental disorder,
42,43,44
 indicates that the biogenetic assumptions 
underlying psychiatric genomics research may have little resonance at both the conceptual level 
(frameworks of descriptive and normative concepts and beliefs) and the practical level (existing and 
normative practices and rituals). Additional contextual realities of different LMIC sites, such as the 
wide range of dialects / languages, lows literacy levels – especially amongst those with mental and 
developmental disorders,
44,45
 – contribute to the substantial and bi-directional translational challenges 
of psychiatric genomics.  
 
The claim that translation and dissemination moves in a single direction, from ‘global’ scientific 
knowledge to ‘local’ beliefs, needs to be critically challenged if psychiatric genomics is to function as 
an asset to existing tools at the local and individual level. Collaboration between biomedical 
knowledge and indigenous perspectives, neither of which are static,
46
 may be necessary to improve 
cross-cultural translation and cultivate mutual understanding around mental health and psychiatric 
genomics.
43,47
 A major area of work in the NeuroGenE programme therefore explores ways in which 
the learning and translational process of psychiatric genomics is multidirectional, so that global 
psychiatric genomics engages seriously with local knowledge systems and beliefs around mental 
disorder in a reciprocal fashion. Core research questions are shown in Box 2a. 
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Issues concerning justice and equity reveal the global-local dilemma in a different form. Significant 
attention has been paid to the structural and systemic challenges facing global mental health in recent 
years.
14,48–51
 Although mental health provision can be unequal within HIC settings, the most extreme 
disparities exist between HIC and LMIC countries. The barriers to equity in global mental health care 
are especially daunting, ranging from poor infrastructure and lack of investment in community-based 
services, training programmes, and public mental health campaigns,
49,50,52
 to socio-economic and 
environmental factors of poverty physical and sexual abuse / exploitation, gender-specific issues,
53,54
 
to restricted civil economic, political, and social rights, and institutionalisation.
48
 Despite 
multinational support to alleviate such barriers,
55
 the lack of tangible inroads in this area indicates two 
shortcomings: first, there is little consensus in terms of priority-setting with regards to where scarce 
funds can improve the lives of people with mental disorder, with solutions ranging from investment in 
human rights and regulatory frameworks,
56
 community-services,
57
 and government initiatives.
58
 
Second, the language of equity, global justice, and global health is often distilled through the prism of 
liberal rights-based language,
59
 but whether it has sufficient normative power to express individual 
entitlements, empower advocacy work and motivate systemic change in different cultural contexts is 
debatable.
17,60,61
  
Box 2a: Core Research Questions on the Impact of Psychiatric Genomics on the Global and Local 
Dilemma  
 To what extent can global psychiatric genomics become ‘localised’?  
 What does ‘translation’ mean in this project? To what extent can cultural / indigenous 
views be reconciled with biogenetic explanations of mental / neurodevelopmental 
disorder? Should ‘reconciliation’ be a goal of respectful scientific translation? 
 How can these local conceptual frameworks and tools potentially enhance, not just the 
practical, clinical implementation of psychiatric genomics research, but Western 
frameworks of mental disorder and mental health practices? 
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Questions of justice and equity are also deeply relevant to issues of global research collaboration, 
specifically around the practices of collaboration amongst stakeholders, which psychiatric genomic 
research will have to navigate so that benefits accrue for local academic centres and individual 
researchers. Global scientific research programmes often encounter tensions between the pragmatic, 
cost-benefit interests of research and the imperative to include local expertise and knowledge. Funder 
expectations, government initiatives, familiarity with legal processes and existing collaborators, as 
well as the influence of scientific clusters (i.e. prominent academic researchers or centres) often 
justify why certain collaborators are favoured as opposed to others.
62
 Yet the legitimacy and 
credibility of global health research often comes through the inclusion of less recognised stakeholders 
within LMICs, particularly given the increasing importance of local understanding and expertise in 
research design. This tension can mean the disproportionate benefit to high-income countries and 
research centres through inequitable practices of collaboration,
63
 which evokes deeper questions 
around the necessary mechanisms for a fair and ethically-grounded global research collaboration that 
encourages mutual respect, reciprocity, and shared ownership.
64
 
 
These pressing political, economic, and social challenges in global mental health policies and research 
draw attention to three fundamental issues within the ethics of psychiatric genomics. First are 
concerns of distributive justice and fairness: in the face of scarce resources in global and local mental 
health programs, critical reflection on the putative justification of financial investment in psychiatric 
genomics, particularly within LMIC settings, is essential. Second are concerns around the ethical 
appropriateness of liberal rights-based language. Indeed, a genomics approach raises difficult 
questions as to who is the rights-holder and whose rights should be protected: the scientific research 
depends on population-wide samples to generate tangible findings, whilst the reciprocal benefits to 
individuals may be inconsequential or non-existent in the first instance. Finally, the nature of 
international scientific collaborations in the name of equity and social justice needs further scrutiny to 
better understand how diverse stakeholders interpret and enact these concepts from their different 
perspectives. These tensions are ripe for further bioethical research, as detailed in Box 2b.  
12 
 
 
 
Further research into the ethical challenges of navigating the global and local will be vital to ensure 
psychiatric genomic research reflects an approach that balances respect for different cultural values 
and local conceptual frameworks,
65,16
 with the pursuit of a just, equitable distribution of global mental 
health resources. 
 
Combating Stigma 
Persons with mental and neurodevelopmental disorders are likely to experience stigma from multiple, 
intersecting angles: from the angle of mental disorder, they can be viewed as dangerous, 
uncontrollable, and unpredictable;
66,67
 from the angle of disability, they can be perceived as helpless, 
less than human, and dependent.
68
 There is also significant self-stigma.
69,70
 Whatever the angle, they 
can be labelled outsiders and are often subject to discriminatory or even inhumane treatment. But the 
complex, divergent anti-stigma strategies used in mental health and disability advocacy respectively 
Box 2b: Ethical Questions on the Impact of Psychiatric Genomics on the Global and Local 
Dilemma  
 What are the cultural and political realities in LMICs and what does equity and justice 
mean to different communities and various stakeholders within these communities 
and in scientific collaborations?  
 Are there general principles of equity and justice in relation to global psychiatric 
genomics research and what obligations are generated out of these principles?  
 How should equity and justice be expressed in psychiatric genomics and mental 
health practices and policies?  
 Does international scientific collaboration drive or hinder equity and justice; does it 
promote better outcomes and for whom? What mechanisms or procedures can be used 
to ensure global collaboration on psychiatric genomics itself is equitable and 
inclusive? 
 How can the differing ideas and research trajectories come together whilst ensuring 
the intellectual integrity of all collaborators?  
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reveal a third major ethical faultline that psychiatric genomics will need to navigate, and depending 
on the approach adopted, this lens could potentially mitigate or worsen the problem of stigma facing 
those with mental and neurodevelopmental disorders and disabilities. 
 
Anti-stigma public health strategies often emphasise the physiological or neurological basis of mental 
disorder to help reduce attributions of individual voluntariness and personal weakness, and in turn, 
social exclusion and rejection.
71
 However the evidence that this is a helpful approach is mixed, with 
some studies indicating heightened perceptions of dangerousness and immutability accompany such 
explanations.
72,73
 By contrast, anti-stigma campaigns in disability advocacy typically focus on the 
social construction of diagnostic labels and disability and downplay biological causes of impairment 
to confront discriminatory attitudes and empower individuals to advocate for their human rights and 
equal participation.
74,75 
 
Different cultural and religious beliefs further complicate this existing tension between social 
construction and biogenetic explanation within the context of global psychiatric genomics.
38,76
 From 
one standpoint, psychiatric genomics could have a substantial role in mitigating the stigma of persons 
with mental and neurodevelopmental disorder in non-Western contexts: emphasis on the inheritance 
of traits and genetic risks might displace indigenous explanations based on individual and/or familial 
moral failure, supernatural causes or being cursed.
17,44,77
 Equally, a psychiatric genomics lens could 
potentially exacerbate essentialist stereotypes and perceived differences among racial groups,
78,79
 
where the racial distribution of certain disorders may negatively influence public perceptions
80
 or 
appear to validate racial prejudices.
81
 A cross-cutting approach promises to generate original research 
around stigma in the context of psychiatric genomics, of which questions include those given in Box 
3. 
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Methodologies 
NeuroGenE takes an expansive view about the methodologies that are needed to undertake this 
ambitious cross-cutting research agenda. Different stages will deploy a variety of methodologies, 
gradually building up an empirical and theoretical evidence base that will function as a vital resource 
for developing future practical and policy recommendations. These stages build on one another, but 
are not necessarily chronologically ordered and may be simultaneously undertaken; different ethical 
questions may also involve vacillating between the methodologies of early and later stages. However, 
the overall NeuroGenE strategy ensures that the final stage of policy recommendations and guidelines 
is substantively informed by prior stages. 
 
Stage 1 involves literature reviews and thematic analyses of existing research in the areas of 
genomics, global mental health, and disability studies in order to survey, systematise, and evaluate the 
regulatory, legal landscape as well as ethics research in these respective areas as they bear on the 
issues within psychiatric genomics. Systematic reviews will synthesise relevant global and country-
specific statistical data that will be used for purposes of comparison as well as provide a contextual 
survey of each potential site for fieldwork in Stage 2. 
 
 
Box 3: Key Ethical Questions on the Impact of Psychiatric Genomics in Addressing Stigma 
 Can genomic explanations of mental disorder help mitigate these stigmatising views? 
Can these help mitigate the subjective effects of stigma?  
 Is there a danger that notions of genomic responsibility / citizenship could perpetuate 
essentialist understandings of race / disability / mental disorder? 
 What does an ethically grounded strategy to combating stigma in LMIC contexts look 
like, particularly in the context of psychiatric genomics? 
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Building on the identified areas of intersecting ethical concerns from the literature / thematic analyses 
and relevant statistical data within systematic reviews, Stage 2 uses ethnographic, qualitative, and 
participatory methodologies to explore various perspectives of key stakeholders of global psychiatric 
genomics. These include local practitioners, individuals affected by mental and neurodevelopmental 
disorders, family members, and local advocacy groups, to explore (i) local knowledge systems, 
beliefs, and cultural meanings around mental health practices; (ii) the portability and translational 
challenges of global mental health and psychiatric genomics concepts; (iii) the perceived interests and 
priorities in mental health care by local stakeholders; (iv) lived experience of stigma. Case studies will 
be developed and a comparative analysis of this data will indicate relevant points of converging and 
diverging interests.  
 
Stage 3 draws on the examination of cultural beliefs and indigenous conceptual frameworks in Stage 2 
and deploys cultural and normative theorising to facilitate critical engagement with biomedical 
concepts and methodological assumptions underlying psychiatric genomics. Even within Western 
contexts, the presumed scientific objectivity of psychiatric concepts and diagnostic classifications 
remain contested. The global context complicates this even further, where issues of power, 
particularly in post-colonial and LMIC settings, warrant careful consideration. Hence, Stage 3 uses 
cultural and normative theorising to critically examine points of contestation and open points of 
dialogue between cultural and scientific meanings. This is of particular importance if psychiatric 
genomics is to play an active role in combating stigma in future applications. 
 
Stage 4 utilises philosophical and conceptual analysis to probe the underlying ethical concepts, 
obligations, and principles (around distributive justice, equity, and human rights) which should guide 
global psychiatric genomics research and its application, taking as its point of departure the 
phenomenological, empirical, and conceptual data generated out of Stages 2 and 3, to engage in 
ethical theorising that reflects the nexus of local-global, cultural-scientific perspectives.  
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Together these different stages will provide a crucial evidence base for practicable recommendations 
at Stage 5, facilitating efforts to address the gap between scientific translation and clinical practice 
and public health policy,
82
 through ethically grounded and context-sensitive strategies. Such policy 
recommendations will take both a short and long term perspective, as some research will be relevant 
for immediate ground level change for persons with neurological disorders, whilst other aspects of 
research will support the development of future policy and practice.  
 
Figure 2: NeuroGenE Methodologies 
 
Guiding Principles and Expected Outputs 
Four core principles guide the NeuroGenE research programme: (i) reciprocity; (ii) collaboration; (iii) 
accountability; and (iv) capacity-building. These principles are operationalised at both procedural and 
substantive levels: 
(i) the process of developing and generating research questions; 
(ii) the practical ethos and virtues of researchers involved in NeuroGenE; 
(iii) the obligations embedded within the overarching NeuroGenE research strategy and 
organisational structure. 
 
The principle of reciprocity is an adaptation of deliberative practices of ‘mutual reason-giving’,83 but 
we understand the term to work inseparably with the principle of collaboration. These principles not 
only denote the equal status of stakeholders, but demand an equitable, mutually respectful, and 
trusting space for deliberation on the values, reasons, and motivations of different conceptual 
frameworks. This is crucial to mitigate the colonialism that can inadvertently shape the intellectual 
sphere: Western, medical and scientific frameworks or normative concepts assume their portability 
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and tend to ignore the reality of non-Western beliefs, traditions and practices related to human 
identity, health and wellbeing.
84,85,86
 The principles of reciprocity and collaboration embed multi-
directional knowledge production to facilitate the kind of cultural exchange that is demanded by a 
truly global orientation towards mental health and psychiatric genomics.  
 
Reciprocity and collaboration with local stakeholders and service-users are also vital to avoid the 
exclusion and discrimination of persons with mental disorder and intellectual disability. Persons with 
mental disorder and intellectual disability are too often treated as subjects or objects of research,
87
 yet 
they may have something fundamentally at stake with the widespread application of psychiatric 
genomics within a precision medicine framework. Direct engagement and dialogue with disabled 
persons organisations (DPOs), mental health advocates, and service-users is necessary so as to probe 
how they believe their lives can improve through the research. Psychiatric genomics is unlikely to 
have little or no buy-in from local communities, or have practical relevance for different cultures or 
local stakeholders, unless reciprocity guides the entire process of learning, knowledge production, and 
practical translation. 
 
The principle of accountability denotes interactions and processes where persons / entities are held to 
account for their choices, reasons, and justifications through a transparent and fair process. 
Accountability is applied in both vertical and horizontal senses: vertical accountability denotes 
responsibility to hierarchical decision-making bodies, such as NeuroGenE’s Advisory Group that will 
be comprised of leading experts in relevant disciplines and strategic partnerships. But more important 
are the mechanisms of horizontal accountability within regional working groups and research 
partners, designed to encourage project collaborators to operate with transparency and mutual 
answerability, and exercise collective oversight of the research programme. 
 
Capacity-building forms the fourth core principle of the NeuroGenE research programme. This 
includes mechanisms to strengthen capacity in bioethical research, collaborative structures, and policy 
and practice expertise. Mentorship and training for local researchers will be provided to develop, 
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conduct, analyse, and publish their work. Other capacity-building activities include the formation of a 
global network of multidisciplinary researchers, within and across institutions. NeuroGenE is 
developing institutional research capacity through partnerships with different organisations, such as 
the African Mental Health Research Initiative (AMARI) and University of Ghana, as well as through 
the provision of postdoctoral training. Meanwhile, the programme provides support for enhancing 
research capacity of individual researchers who participate in the project’s local working groups, such 
as the African Ethics Working Group (AEWG) comprised of early and mid-career individual 
academics from Moi University, Addis Ababa University, University of Cape Town, and Makerere 
University. Support mechanisms include core research, training and grant funding to enable the 
pursuit of individual and collaborative research projects at various levels of inquiry of the ethics of 
psychiatric genomics that will eventually feed into initiatives to enhance capacity within institutional 
review boards and amongst public health policy makers.  
 
The expected outputs of the NeuroGenE programme of research include: 
 The establishment of a diverse, interdisciplinary, and sustainable research network devoted to 
the ethics of psychiatric genomics and regional centres of training, capacity-building, and 
academic research; 
 Cutting edge bioethical research papers and reports; 
 The development of policy guidelines and recommendations to address the prospective 
application of psychiatric genomics in public health and clinical practice; 
 Sustainable relationships with DPOs and service user organisations which feed into future 
research and policy initiatives. 
 
Conclusion 
Global psychiatric genomics is at the forefront of scientific research and has the potential to transform 
psychiatric nosology, public health policy, and the nature of clinical interventions. We have drawn on 
the literatures of global mental health, bioethics and disability studies to frame a set of reasons why 
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the ethics of global psychiatric genomics will form a necessary part of genomic programmes of 
research in mental health. The NeuroGenE project establishes a cross-cutting, interdisciplinary 
programme which embeds ethics research within the science and establishes a proactive agenda of 
work around the ethical implications and challenges of psychiatric genomics in the global context. 
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